CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

azithromycin

· ingredient azithromycinAntibiotics· AZITHROMYCIN DIHYDRATE 100 mg/5mL; AZITHROMYCIN DIHYDRATE 200 mg/5mL; AZITHROMYCIN MONOHYDRATE 100 mg/5mL; AZITHROMYCIN MONOHYDRATE 200 mg/5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.23842
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other azithromycin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
azithromycin$0.28000+$0.04160
Azithromycin$0.59739+$0.35900
azithromycin$0.80721+$0.56880
AZASITE$98.36+$98.12

Medicare Part D coverage · CY2026

On 319 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.